



Journal of Frontiers in Multidisciplinary Research

A Deep Learning Approach to Predicting Diabetes Mellitus Using Electronic Health Records

Bamidele Samuel Adelusi ^{1*}, Damilola Osamika ², MariaTheresa Chinyeaka Kelvin-Agwu ³,
Ashiata Yetunde Mustapha ⁴, Nura Ikhalea ⁵

¹ SigmaXplus Solutions LLC, USA

² Department of Environmental Health, Margaret Mosunmola College of Health Science and Technology, Nigeria

³ Independent Researcher, Lagos, Nigeria

⁴ Kwara State Ministry of Health, Nigeria

⁵ Independent Researcher, Texas, USA

* Corresponding Author: **Bamidele Samuel Adelusi**

Article Info

E-ISSN: 3050-9726

P-ISSN: 3050-9718

Volume: 03

Issue: 01

January-June 2022

Received: 24-12-2021

Accepted: 01-12-2021

Published: 20-01-2022

Page No: 47-56

Abstract

Diabetes Mellitus (DM) is a chronic metabolic disorder that poses a significant global health burden, affecting millions worldwide. Early detection and prediction of diabetes are critical for timely intervention and improved patient outcomes. The increasing availability of Electronic Health Records (EHRs) has provided a valuable data source for leveraging deep learning techniques to enhance diabetes prediction. This study explores the application of deep learning models in predicting diabetes using structured and unstructured EHR data. This review various deep learning architectures, including Artificial Neural Networks (ANNs), Convolutional Neural Networks (CNNs) for medical imaging, Recurrent Neural Networks (RNNs) and Long Short-Term Memory (LSTM) networks for sequential health data analysis, and Autoencoders for feature extraction and anomaly detection. The performance of these models is evaluated using metrics such as accuracy, precision, recall, F1-score, and the Area under the Receiver Operating Characteristic Curve (AUC-ROC). Additionally, we discuss data preprocessing techniques, including handling missing values, normalization, and feature selection, which are crucial for optimizing model performance. Despite the promising advancements, challenges such as data privacy, class imbalance, model interpretability, and generalizability across diverse populations remain significant barriers to widespread clinical adoption. We highlight emerging trends such as federated learning for privacy-preserving AI, the integration of wearable health devices for real-time monitoring, and explainable AI (XAI) to enhance trust and transparency in deep learning-based diabetes prediction. This underscores the potential of deep learning in transforming diabetes prediction and management by providing accurate, scalable, and automated diagnostic tools. Future research should focus on improving model robustness, enhancing interpretability, and integrating deep learning models into real-world clinical workflows for effective diabetes prevention and personalized healthcare interventions.

DOI: <https://doi.org/10.54660/IJFMR.2022.3.1.47-56>

Keywords: Deep learning approach, Diabetes mellitus, Electronic health records, Review

1. Introduction

Diabetes Mellitus (DM) is a chronic metabolic disorder characterized by elevated blood glucose levels resulting from impaired insulin production or action (Gbadegesin *et al.*, 2022). It is a major global health concern, affecting over 537 million adults worldwide, with projections indicating a rise to 783 million by 2045.

The disease is associated with severe complications, including cardiovascular disease, kidney failure, neuropathy, and retinopathy, leading to increased morbidity, mortality, and healthcare costs. Early detection and intervention are crucial in managing diabetes effectively, reducing complications, and improving patient quality of life (Bristol-Alagbariya *et al.*, 2022). However, traditional diagnostic approaches rely on biochemical testing and clinical assessments, which may not always detect diabetes in its early stages.

In recent years, Electronic Health Records (EHRs) have emerged as a valuable data source for diabetes prediction (Adewoyin, 2022; Ozobu *et al.*, 2022). EHRs contain vast amounts of patient data, including demographic information, laboratory test results, medication history, and clinical notes, providing a comprehensive overview of an individual's health status. By leveraging EHRs, healthcare professionals can identify risk factors and patterns that contribute to the early detection of diabetes (Ajayi and Akerele, 2022). However, the sheer volume and complexity of EHR data require advanced computational methods for efficient analysis and interpretation.

Deep learning has revolutionized healthcare analytics by enabling the extraction of meaningful insights from large, complex datasets (Collins *et al.*, 2022). Unlike traditional machine learning models, deep learning algorithms, such as Artificial neural networks (ANNs), convolutional neural networks (CNNs), and long short-term memory (LSTM) networks, can automatically learn intricate patterns and relationships within EHR data. These models have demonstrated superior predictive accuracy in various medical applications, including disease diagnosis, prognosis, and personalized treatment planning. In the context of diabetes prediction, deep learning offers the potential to enhance early detection, facilitate proactive interventions, and optimize patient management strategies (Hamza *et al.*, 2022).

This aims to explore the application of deep learning techniques in predicting diabetes mellitus using EHR data. Specifically, it investigates various deep learning architectures, their effectiveness in diabetes prediction, and the challenges associated with their implementation in clinical practice (Bristol-Alagbariya *et al.*, 2022). The study also discusses data preprocessing methods, model evaluation metrics, and emerging trends such as federated learning and explainable AI (XAI) to improve model transparency and trust. By providing a systematic analysis of deep learning-based diabetes prediction, this contributes to the development of advanced, data-driven solutions for improving diabetes prevention and management.

2. Methodology

A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to assess deep learning approaches for predicting Diabetes Mellitus (DM) using Electronic Health Records (EHRs). The methodology involved four key stages: identification, screening, eligibility, and inclusion.

In the identification phase, relevant studies were retrieved from multiple electronic databases, including PubMed, IEEE Xplore, Scopus, and Google Scholar. The search strategy combined keywords such as “deep learning,” “diabetes mellitus prediction,” “electronic health records,” “machine learning in diabetes,” and “artificial intelligence in healthcare.” Boolean operators (AND, OR) were applied to

refine search queries, ensuring comprehensive coverage of relevant literature. Additional references were identified through citation tracking of key articles.

During the screening phase, duplicate records were removed using automated and manual approaches. The titles and abstracts of the remaining studies were reviewed to determine their relevance to deep learning-based diabetes prediction using EHR data. Studies that focused solely on traditional statistical models, non-EHR data sources, or unrelated medical conditions were excluded.

The eligibility stage involved a detailed assessment of full-text articles based on predefined inclusion and exclusion criteria. Inclusion criteria required studies to (1) utilize deep learning models for diabetes prediction, (2) use EHR data as a primary source, (3) report performance metrics such as accuracy, precision, recall, F1-score, and AUC-ROC, and (4) be published in peer-reviewed journals or conference proceedings in English. Exclusion criteria included studies lacking sufficient methodological details, review articles without primary experimental results, and studies using only synthetic datasets.

Finally, in the inclusion phase, eligible studies were reviewed for data extraction and synthesis. Extracted information included study characteristics, dataset sources, deep learning architectures, preprocessing techniques, performance metrics, and key findings. A PRISMA flowchart was developed to illustrate the study selection process, ensuring transparency and reproducibility in the review methodology.

2.1 Data sources and preprocessing

Deep learning models for diabetes mellitus (DM) prediction heavily rely on high-quality data for effective training and inference. Electronic Health Records (EHRs) serve as a primary data source, containing vast amounts of structured and unstructured patient information (Charles *et al.*, 2022). However, for deep learning models to generate accurate predictions, comprehensive data preprocessing is essential. This includes handling missing data, normalizing and standardizing variables, and implementing effective feature engineering techniques.

EHRs provide an extensive collection of patient health information, including demographics, medical history, laboratory results, prescriptions, and lifestyle factors. These records enable deep learning models to identify patterns associated with diabetes onset and progression. Unlike traditional predictive models that rely on a limited set of variables, deep learning approaches can analyze large, multidimensional datasets extracted from EHRs, allowing for more robust predictive capabilities (Adepoju *et al.*, 2022). Key sources of EHR data include hospital management systems, national health databases, and private healthcare providers. Publicly available datasets, such as the MIMIC-III (Medical Information Mart for Intensive Care) and NHANES (National Health and Nutrition Examination Survey), have also been used in research for diabetes prediction. These datasets provide a diverse range of patient information, enabling researchers to develop models with greater generalizability.

Several critical patient attributes influence the accuracy of deep learning models in predicting diabetes (Ige *et al.*, 2022). These include as shown in figure 1; Age, gender, ethnicity, socioeconomic status. Past diagnoses, family history of diabetes, comorbidities (e.g., hypertension, obesity). Blood glucose levels, hemoglobin A1c (HbA1c), lipid profile,

kidney function markers. Physical activity levels, smoking status, dietary habits, medication adherence (Adepoju *et al.*, 2022). Integrating these diverse attributes into predictive models enhances the ability to detect diabetes risk early, enabling timely interventions and personalized treatment strategies.




Fig 1: Data for accuracy of deep learning models in predicting diabetes

EHR datasets often contain missing values due to incomplete documentation or variability in clinical assessments (Adepoju *et al.*, 2022). Handling missing data is crucial for maintaining model accuracy and reliability. Various imputation techniques can be applied, including; replacing missing numerical values with the mean and categorical values with the mode. This method is simple but may introduce bias if the missing data is not random. Predicts missing values based on similar patient records. KNN considers the proximity of data points in feature space, providing a more adaptive imputation technique. Generates multiple plausible values for missing entries based on probabilistic modeling, improving the robustness of predictions. Selecting the appropriate imputation method depends on the extent of missingness and the characteristics of the dataset. More advanced deep learning architectures can also learn to handle missing values directly, reducing reliance on explicit imputation.

Machine learning and deep learning algorithms require input features to be scaled appropriately for optimal performance. Normalization and standardization are two commonly used techniques; Normalization (Min-Max Scaling), rescales numerical data to a fixed range, typically [0,1] or [-1,1]. This technique is beneficial when data have varying ranges (Akinade *et al.*, 2022). Standardization (Z-score Scaling), transforms data to have zero mean and unit variance, ensuring consistent feature distribution across different variables. For deep learning models, improper scaling can lead to poor convergence or biased weight updates. Normalizing continuous features such as blood glucose levels and HbA1c ensures that all input data contribute equally to model learning (Ajayi and Akerele, 2022).

Feature engineering plays a critical role in enhancing model interpretability and performance. Effective feature selection ensures that only the most relevant attributes are used,

reducing computational complexity and avoiding overfitting. Common feature engineering techniques include; Principal component analysis (PCA), reduces the dimensionality of the dataset while preserving essential variance, helping improve model efficiency (Egbunu *et al.*, 2022). Recursive feature elimination (RFE), iteratively removes less significant features based on their impact on model performance. Feature encoding, convert's categorical variables (e.g., ethnicity, smoking status) into numerical representations suitable for deep learning models (e.g., one-hot encoding, embedding layers). By selecting the most informative features, deep learning models can focus on critical predictors of diabetes, leading to more accurate and generalizable predictions. Data preprocessing is a crucial step in developing deep learning models for diabetes prediction using EHRs. By effectively handling missing data, normalizing input features, and selecting relevant attributes, researchers can improve model accuracy and reliability. Leveraging comprehensive patient records enhances the ability to detect diabetes at an early stage, ultimately contributing to better disease management and improved patient outcomes (Adegoke *et al.*, 2022).

2.2 Deep learning models for diabetes prediction

Diabetes Mellitus (DM) is a chronic metabolic disorder affecting millions worldwide, with significant health and economic burdens (Opia *et al.*, 2022). Early and accurate prediction of diabetes is crucial for preventing complications and improving patient outcomes. Traditional machine learning models, such as logistic regression and decision trees, have been used for diabetes prediction, but deep learning models have demonstrated superior performance in handling complex medical data. Deep learning techniques, including artificial neural networks (ANNs), convolutional neural networks (CNNs), recurrent neural networks (RNNs), long short-term memory (LSTM) networks, Autoencoders, and Generative Adversarial Networks (GANs), offer advanced capabilities in analyzing Electronic Health Records (EHRs) and medical images (Govender *et al.*, 2022). This explores the applications of these models and compares their effectiveness with traditional machine learning approaches. Artificial neural networks (ANNs) are a foundational deep learning model inspired by the human brain. They consist of interconnected layers of artificial neurons that process and learn patterns from data. In diabetes prediction, ANNs analyze structured EHR data, such as patient demographics, clinical history, lab test results, and lifestyle factors, to identify individuals at risk (Adepoju *et al.*, 2022). ANNs are particularly effective in detecting non-linear relationships between multiple risk factors, which traditional machine learning models struggle to capture. Multi-layer perceptron (MLP) networks, a common type of ANN, have been widely used in diabetes prediction. They employ backpropagation and optimization algorithms like stochastic gradient descent to improve predictive accuracy (Collins *et al.*, 2022). By training on large-scale EHR datasets, ANNs can detect early warning signs of diabetes, enabling timely medical interventions.

Convolutional neural networks (CNNs) are designed for image processing and have been extensively used in medical image analysis, particularly for detecting diabetic complications such as diabetic retinopathy (DR). DR is a diabetes-induced eye disease that can lead to blindness if not diagnosed early. CNNs utilize convolutional layers to extract spatial features from images, making them highly effective in

identifying abnormalities in retinal scans (Adelodun *et al.*, 2018). These models process high-resolution fundus images, detecting microaneurysms, hemorrhages, and exudates, which are indicators of DR. Research has shown that CNN-based DR detection systems can achieve diagnostic accuracy comparable to that of ophthalmologists. When integrated with EHR data, CNNs enhance diabetes prediction models by incorporating visual biomarkers.

Recurrent neural networks (RNNs) are designed to handle sequential data and are particularly useful for analyzing time-series information in EHRs. Since diabetes progression involves dynamic changes in physiological and biochemical markers, RNNs can model these temporal dependencies to predict disease onset (Tomassoni *et al.*, 2013). However, traditional RNNs suffer from vanishing gradient issues, limiting their ability to capture long-term dependencies. Long Short-Term Memory (LSTM) networks, an advanced variant of RNNs, overcome this limitation by incorporating memory cells that retain information over extended periods. LSTMs have been successfully applied in diabetes prediction by analyzing sequential data, such as glucose levels, medication adherence, and lifestyle changes. These models enable continuous patient monitoring and facilitate personalized risk assessment.

Autoencoders and generative adversarial networks (GANs) play a crucial role in feature extraction and data augmentation, addressing challenges such as imbalanced datasets and missing values in EHRs. Autoencoders, these unsupervised deep learning models compress input data into a lower-dimensional representation and reconstruct it, effectively identifying hidden patterns in medical records (Matthew *et al.*, 2021). Autoencoders help extract meaningful features from high-dimensional EHR data, improving the performance of predictive models. Generative adversarial networks (GANs), consist of two competing neural networks a generator and a discriminator that work together to create realistic synthetic data. In diabetes prediction, GANs are used to generate synthetic patient records, which help mitigate class imbalance issues, particularly when early-stage diabetes cases are underrepresented. This augmentation improves model generalization and robustness.

Deep learning models have demonstrated significant advantages over traditional machine learning methods in diabetes prediction (Jahun *et al.*, 2021). The key differences between these approaches include; Traditional machine learning models require manual feature selection, whereas deep learning models automatically learn hierarchical representations from raw data, leading to improved accuracy. Deep learning models, particularly ANNs and autoencoders, efficiently process large and complex datasets, whereas traditional models struggle with feature interactions. RNNs and LSTMs outperform traditional models like random forests and support vector machines (SVMs) in analyzing sequential health data, such as glucose fluctuations and lifestyle changes (Austin-Gabriel *et al.*, 2021). CNNs excel in analyzing retinal scans and other medical images, whereas traditional machine learning relies on handcrafted features that may not capture intricate patterns. One limitation of deep learning is its "black-box" nature, making it challenging to interpret predictions.

Traditional models, such as decision trees, offer better explainability, which is critical in clinical settings. Deep learning has revolutionized diabetes prediction by leveraging EHRs and medical imaging to provide accurate and timely risk assessments. ANNs, CNNs, RNNs, LSTMs, autoencoders, and GANs offer advanced capabilities in analyzing structured and unstructured medical data. Compared to traditional machine learning approaches, deep learning models demonstrate superior performance in feature extraction, sequential data analysis, and medical image processing. Future research should focus on enhancing model interpretability, integrating explainable AI techniques, and addressing ethical concerns to ensure the widespread adoption of deep learning in diabetes prediction and management (Hussain *et al.*, 2021; Adepoju *et al.*, 2022).

2.3 Model training and performance evaluation

The success of a deep learning model for diabetes prediction depends on effective training and rigorous performance evaluation. The training process involves splitting the dataset, optimizing loss functions, and utilizing appropriate evaluation metrics to ensure model accuracy and reliability (Ike *et al.*, 2021). This discusses key aspects of model training and performance evaluation, including data splitting, optimization algorithms, evaluation metrics, and validation strategies.

Before training a deep learning model, the dataset must be divided into three subsets; Training Set, this subset (typically 70–80% of the dataset) is used to train the model (Tomassoni *et al.*, 2013). It enables the neural network to learn patterns from the data by adjusting its weights through iterative optimization. Validation Set, this subset (10–15% of the dataset) is used to tune hyperparameters, prevent overfitting, and assess model performance during training. The model does not learn from this set but uses it for parameter adjustments. Test Set, the remaining 10–15% of the dataset is used for final evaluation to assess the model's ability to generalize to unseen data. The test set provides an unbiased estimate of model performance. A well-balanced split ensures that the model is trained on sufficient data while also maintaining independent validation and testing phases.

Deep learning models require loss functions and optimization algorithms to minimize errors and improve performance. The choice of a loss function depends on the problem type; binary cross-entropy loss, used for binary classification tasks like diabetes prediction (diabetic vs. non-diabetic). Mean squared error (MSE), used for regression-based predictions, such as estimating blood glucose levels (Kuo *et al.*, 2019). Optimization algorithms, these algorithms adjust model parameters to minimize the loss function as shown in figure 2 below; Adam (Adaptive moment estimation), a widely used optimizer that combines momentum-based gradient descent and adaptive learning rates for faster convergence. RMSprop (Root mean square propagation), helps stabilize learning in non-stationary environments by adjusting learning rates based on recent gradients. Stochastic gradient descent (SGD), simple yet effective optimizer, though it requires careful tuning of the learning rate. Choosing the appropriate loss function and optimizer is critical for achieving stable and efficient model training.




Fig 2: Optimization algorithms model parameters

Assessing model performance involves multiple evaluation metrics to ensure reliability in clinical applications (Olamijuwon, 2020). Accuracy, measures the percentage of correctly predicted cases out of all cases. While useful, accuracy alone can be misleading when dealing with imbalanced datasets (e.g., when diabetes-positive cases are much fewer than diabetes-negative cases). Precision (Positive Predictive Value), the proportion of correctly predicted diabetic cases out of all predicted positive cases. Recall (Sensitivity or True Positive Rate), the proportion of correctly identified diabetic cases out of all actual diabetic cases. F1-score, the harmonic means of precision and recall, balancing false positives and false negatives. It is useful when class distribution is imbalanced. Sensitivity (Recall), measures the ability to detect true diabetic cases (Oyedokun, 2019). High sensitivity ensures minimal false negatives, which is crucial in medical diagnostics. specificity (True Negative Rate), measures the ability to correctly identify non-diabetic cases, reducing false positives. Area under the curve – receiver operating characteristic (AUC-ROC), the ROC curve plots sensitivity (true positive rate) against 1-specificity (false positive rate) at different threshold levels. AUC-ROC score, measures model discrimination ability. AUC values range from 0.5 (random chance) to 1.0 (perfect classification). AUC-ROC is a preferred metric for diabetes prediction models, as it evaluates overall classification performance across different thresholds (Oladosu *et al.*, 2021).

To ensure the robustness of deep learning models, proper validation strategies are required. K-Fold Cross-Validation, the dataset is split into K subsets. The model is trained K times, each time using a different subset as the validation set and the remaining data as the training set. This reduces variance and improves generalization. Stratified K-Fold Cross-Validation, ensures that each fold maintains the same class distribution as the entire dataset, preventing bias in imbalanced datasets (Agho *et al.*, 2021). A deep learning model trained on one dataset may not perform well on different datasets due to variations in data distributions. External validation involves testing the model on independent datasets from different hospitals or regions to assess its generalizability. Training and evaluating deep learning models for diabetes prediction requires careful data splitting, selection of loss functions and optimization

algorithms, and appropriate performance metrics. Metrics like accuracy, precision, recall, F1-score, sensitivity, specificity, and AUC-ROC provide a comprehensive assessment of model reliability. Cross-validation and external validation enhance the robustness and generalizability of models, ensuring their effectiveness in real-world clinical settings (Nwaozumudoh *et al.*, 2021). Future work should focus on improving interpretability and reducing bias in AI-driven diabetes prediction models to facilitate widespread clinical adoption.

2.4 Challenges and Limitations

The integration of deep learning with electronic health records (EHRs) for diabetes prediction has shown significant promise (Odio *et al.*, 2021). However, several challenges and limitations hinder its widespread adoption in clinical settings. These include data privacy and security concerns, class imbalance issues in predictive models, interpretability and explainability of deep learning models, and computational complexity and scalability challenges. Addressing these limitations is essential for ensuring the reliability, ethical integrity, and effectiveness of AI-driven healthcare solutions. Electronic health records (EHRs) contain sensitive patient information, raising critical concerns about data privacy and security (Oluokun, 2021). Regulations such as the health insurance portability and accountability act (HIPAA) in the United States and the general data protection regulation (GDPR) in Europe impose strict guidelines on data usage, sharing, and protection. HIPAA compliance, requires healthcare organizations to implement safeguards for patient data, ensuring confidentiality, integrity, and availability (Dienagha *et al.*, 2021). Any AI system accessing EHRs must adhere to these regulations to prevent unauthorized access and data breaches. GDPR compliance, imposes strict rules on data collection, processing, and storage, granting patients the right to access, modify, and delete their data. AI models trained on European patient data must follow these privacy regulations. Ensuring data security involves encryption, secure data transmission, and access controls. Additionally, privacy-preserving techniques such as federated learning and differential privacy can help train models without exposing raw patient data (Adewoyin, 2021).

One of the key challenges in developing deep learning models for diabetes prediction is class imbalance, where the number of non-diabetic cases significantly outweighs the number of diabetic cases. This imbalance can lead to biased models that favor the majority class, resulting in poor sensitivity (recall) for diabetic patients. A model trained on imbalanced data may achieve high overall accuracy but fail to detect diabetes cases effectively (Akinade *et al.*, 2021). This can have severe consequences in clinical settings, as missed diagnoses may delay treatment. Solutions to address class imbalance; Resampling techniques, oversampling the minority class (e.g., using Synthetic minority over-sampling technique (SMOTE)) or undersampling the majority class to balance the dataset. Cost-sensitive learning, assigning higher misclassification penalties to diabetic cases to ensure the model prioritizes correct predictions for at-risk patients. Ensemble methods, combining multiple models trained on different data distributions to improve classification performance (Elujide *et al.*, 2021). Addressing class imbalance is crucial for ensuring that deep learning models provide equitable and clinically useful predictions. Deep learning models, particularly deep neural networks,

operate as "black boxes," making their predictions difficult to interpret. In healthcare, where decisions must be explainable and justifiable, the lack of model transparency poses a significant challenge. Physicians and healthcare providers need to understand how AI models reach their conclusions to build trust and validate predictions (Hassan *et al.*, 2021). Regulatory bodies require explanations for AI-driven diagnoses to ensure ethical and legal accountability. Highlighting key features in EHRs that influence model predictions. SHAP (shapley additive explanations) and LIME (local interpretable model-agnostic explanations): Providing insights into feature importance and individual predictions. Explainable AI (XAI), developing inherently interpretable models, such as rule-based neural networks, to improve transparency. Improving model interpretability can facilitate clinical adoption and enhance physician-AI collaboration in diabetes diagnosis.

Deep learning models, especially those using complex architectures such as convolutional neural networks (CNNs) and recurrent neural networks (RNNs), require significant computational resources for training and inference (Ajayi and Akerele, 2021). Challenges of computational complexity; Training deep learning models on large-scale EHR datasets demands high-performance computing resources (GPUs, TPUs). Fine-tuning hyperparameters and optimizing large networks increase processing time and memory usage. Implementing deep learning models in real-world healthcare settings requires integrating them with hospital IT infrastructure, which may lack the necessary computational capabilities. Deploying models across multiple institutions introduces data heterogeneity, where variations in EHR formats, data collection methods, and patient demographics affect model generalizability. Potential solutions; Leveraging cloud computing platforms to enable scalable model training and real-time predictions. Running lightweight models on local hospital servers or mobile devices to reduce dependency on centralized computing resources (Tomassoni *et al.*, 2013). While deep learning has the potential to revolutionize diabetes prediction, several challenges must be addressed to ensure its clinical viability. Data privacy and security concerns necessitate compliance with HIPAA and GDPR regulations, while class imbalance issues require advanced resampling and cost-sensitive learning techniques. The interpretability of AI models must be improved to foster trust among healthcare professionals, and computational complexity must be managed to enable scalability. By overcoming these challenges, deep learning can play a transformative role in early diabetes detection and personalized patient care.

2.5 Future directions and innovations

Advancements in deep learning continue to revolutionize healthcare, particularly in the prediction and management of chronic diseases like diabetes mellitus. Emerging innovations, including real-time health monitoring, privacy-preserving AI models, explainable AI (XAI), personalized prediction models, and AI-driven decision support systems, are shaping the future of diabetes prediction and management (Nasuti *et al.*, 2008; Tayebati *et al.*, 2013). These innovations aim to enhance predictive accuracy, improve patient engagement, and ensure seamless integration of AI technologies into clinical workflows.

The proliferation of wearable health devices, such as smartwatches and continuous glucose monitors (CGMs),

offers an unprecedented opportunity for real-time diabetes monitoring and prediction. Deep learning models can process continuous physiological data, including heart rate, blood glucose levels, activity levels, and sleep patterns, to detect early signs of diabetes and its complications. Advantages of real-time monitoring; Early detection of blood glucose fluctuations before they lead to severe complications. Personalized lifestyle recommendations based on real-time data trends. Improved patient adherence by providing instant feedback and actionable insights. Deep learning techniques such as recurrent neural networks (RNNs) and long short-term memory (LSTM) networks are particularly suited for analyzing time-series data from wearables. by integrating these models with internet of things (IoT) platforms, healthcare providers can enable continuous and remote diabetes management, reducing hospital visits and improving patient outcomes (Tayebati *et al.*, 2013). A critical challenge in AI-driven healthcare applications is maintaining data privacy and security while ensuring model effectiveness. Federated learning (FL) offers a solution by enabling AI models to be trained across multiple institutions without sharing raw patient data. How federated learning works; AI models are trained locally on patient data stored within each healthcare institution. Only the learned model updates (and not the raw data) are transmitted to a central server for aggregation. This decentralized approach ensures compliance with regulations such as HIPAA and GDPR while preserving data integrity (Tomassoni *et al.*, 2012). Benefits of federated learning for diabetes prediction as shown in figure 3; Sensitive patient data remains within local hospital systems. Leveraging diverse datasets from multiple institutions helps build robust and unbiased prediction models (Suri *et al.*, 2020). Minimizing the need for centralized data storage mitigates cybersecurity threats. Federated learning represents a scalable and secure approach to developing AI-powered diabetes prediction systems, ensuring broader adoption across healthcare networks (Alli and Dada, 2021).




Fig 3: Benefits of federated learning for diabetes prediction

One of the key barriers to AI adoption in healthcare is the black-box nature of deep learning models, which makes it difficult for clinicians to interpret predictions (Sendak *et al.*, 2020). Explainable AI (XAI) techniques aim to bridge this gap by providing transparent and interpretable insights into

how AI models make decisions (Matthew *et al.*, 2021). Key XAI techniques in diabetes prediction; SHAP (shapley additive explanations), identifies which patient features (e.g., blood glucose levels, BMI, family history) contribute most to the model's decision. LIME (local interpretable model-agnostic explanations), generates human-readable explanations for individual predictions. Attention mechanisms, highlights critical patient attributes that influence AI-driven predictions. By improving interpretability, XAI fosters clinician trust, regulatory compliance, and ethical AI deployment, ensuring that AI-driven decisions are transparent and actionable in diabetes care. Traditional diabetes prediction models rely primarily on structured EHR data, but future advancements will integrate multi-modal health data, including; Genomic data (e.g., genetic predisposition to diabetes). Metabolomics and proteomics data (biochemical markers linked to diabetes progression). Lifestyle and behavioral data (collected from wearables and patient surveys). Medical imaging (e.g., retinal scans for diabetic retinopathy detection). Deep learning models, particularly multi-modal neural networks, can analyze these diverse data sources simultaneously, improving the accuracy of personalized diabetes risk assessment (Jahun *et al.*, 2021). Advantages of personalized ai models; tailored treatment plans, improved early detection, precision medicine integration. By leveraging multi-modal health data, AI can enhance predictive capabilities and enable precision healthcare strategies, ultimately improving patient outcomes. AI-powered clinical decision support systems (CDSS) are emerging as valuable tools in diabetes management, assisting healthcare providers in diagnosis, treatment planning, and patient monitoring. Key features of AI-Driven CDSS; Identifying high-risk patients for early intervention. Optimizing insulin therapy based on patient history. Notifying clinicians of critical changes in patient health. Deep learning models integrated into electronic health record (EHR) systems can analyze patient data in real time, providing evidence-based insights to assist clinicians in making informed decisions (Bidemi *et al.*, 2021). Benefits of AI-Driven decision support in diabetes care; automating routine tasks allows healthcare providers to focus on critical cases. AI-driven insights improve early detection and reduce diagnostic errors. Real-time AI recommendations lead to proactive diabetes management. By enhancing collaboration between AI and healthcare professionals, decision support systems contribute to more efficient, data-driven clinical workflows, ultimately leading to better patient care. The future of AI-driven diabetes prediction and management is shaped by cutting-edge innovations in deep learning and healthcare technology. The integration of AI with wearable health devices enables real-time monitoring, while federated learning ensures data privacy and security (Dirlikov *et al.*, 2021). The adoption of explainable AI (XAI) fosters trust among clinicians, and multi-modal health data integration paves the way for personalized diabetes prediction models. Moreover, AI-powered clinical decision support systems enhance diabetes management by assisting healthcare professionals in early diagnosis and treatment planning (Wang *et al.*, 2021). By addressing current limitations and embracing these future directions, AI has the potential to transform diabetes care, improving early detection, personalized treatment, and overall patient outcomes. Continued research and collaboration between AI developers, clinicians, and healthcare policymakers will be

essential for realizing the full potential of deep learning in diabetes management (Atta *et al.*, 2021; Raman *et al.*, 2021).

3. Conclusion

Deep learning has emerged as a powerful tool in predicting and managing Diabetes Mellitus, leveraging electronic health records (EHRs), wearable health data, and advanced neural networks. Key findings indicate that artificial neural networks (ANNs), convolutional neural networks (CNNs), recurrent neural networks (RNNs), and long short-term memory (LSTM) models significantly outperform traditional machine learning approaches in diabetes prediction. These models efficiently process complex, high-dimensional health data, providing early detection, accurate risk assessment, and real-time monitoring capabilities. Furthermore, techniques like autoencoders and Generative Adversarial Networks (GANs) enhance data augmentation and feature extraction, improving model performance and generalization.

The potential impact of deep learning on diabetes prevention and management is profound. AI-driven real-time monitoring with wearable devices enables early intervention, reducing the risk of complications. Federated learning ensures privacy-preserving AI deployment, addressing critical concerns regarding patient data security and regulatory compliance. Additionally, Explainable AI (XAI) enhances the interpretability of deep learning models, fostering trust among clinicians and enabling data-driven decision support systems for personalized treatment strategies.

Despite these advancements, several challenges remain. Class imbalance, computational complexity, and regulatory concerns hinder large-scale implementation. Future research should focus on integrating multi-modal health data, improving model interpretability, and developing scalable, privacy-preserving AI frameworks. Collaboration between AI researchers, clinicians, and policymakers is essential for clinical validation and real-world deployment.

Ultimately, AI holds transformative potential in diabetes care, providing early risk prediction, precision medicine, and automated clinical decision-making. By addressing current limitations and advancing AI integration in healthcare, deep learning can revolutionize diabetes prevention, diagnosis, and management, significantly improving patient outcomes and reducing the global burden of the disease.

4. References

1. Adegoke SA, Oladimeji OI, Akinlosotu MA, Akinwumi AI, Matthew KA. HemoTypeSC point-of-care testing shows high sensitivity with alkaline cellulose acetate hemoglobin electrophoresis for screening hemoglobin SS and SC genotypes. *Hematology, Transfusion and Cell Therapy*. 2022;44(3):341–5.
2. Adelodun AM, Adekanmi AJ, Roberts A, Adeyinka AO. Effect of asymptomatic Plasmodium parasitemia on the uterine and umbilical artery blood flow impedance in third trimester singleton Southwestern Nigerian pregnant women. *Tropical Journal of Obstetrics and Gynaecology*. 2018;35(3):333–41.
3. Adepoju AH, Austin-Gabriel BLESSING, Eweje ADEOLUWA, Collins ANUOLUWAPO. Framework for automating multi-team workflows to maximize operational efficiency and minimize redundant data handling. *IRE Journals*. 2022;5(9):663–4.
4. Adepoju PA, Adeola S, Ige B, Chukwuemeka C, Oladipupo Amoo O, Adeoye N. Reimagining multi-

- cloud interoperability: A conceptual framework for seamless integration and security across cloud platforms. *Open Access Research Journal of Science and Technology*. 2022;4(1):71–82.
5. Adepoju PA, Austin-Gabriel B, Ige AB, Hussain NY, Amoo OO, Afolabi AI. Machine learning innovations for enhancing quantum-resistant cryptographic protocols in secure communication. *Open Access Research Journal of Multidisciplinary Studies*. 2022;4(1):131–9.
 6. Adepoju PA, Oladosu SA, Ige AB, Ike CC, Amoo OO, Afolabi AI. Next-generation network security: Conceptualizing a unified, AI-powered security architecture for cloud-native and on-premise environments. *International Journal of Science and Technology Research Archive*. 2022;3(2):270–80.
 7. Adewoyin MA. Developing frameworks for managing low-carbon energy transitions: overcoming barriers to implementation in the oil and gas industry. 2021.
 8. Adewoyin MA. Advances in risk-based inspection technologies: Mitigating asset integrity challenges in aging oil and gas infrastructure. 2022.
 9. Agho G, Ezeh MO, Isong M, Iwe D, Oluseyi KA. Sustainable pore pressure prediction and its impact on geo-mechanical modelling for enhanced drilling operations. *World Journal of Advanced Research and Reviews*. 2021;12(1):540–57.
 10. Ajayi A, Akerele JI. A high-impact data-driven decision-making model for integrating cutting-edge cybersecurity strategies into public policy, governance, and organizational frameworks. *International Journal of Multidisciplinary Research and Growth Evaluation*. 2021;2(1):623–37.
 11. Ajayi A, Akerele JI. A practical framework for advancing cybersecurity, artificial intelligence, and technological ecosystems to support regional economic development and innovation. *International Journal of Multidisciplinary Research and Growth Evaluation*. 2022;3(1):700–13.
 12. Ajayi A, Akerele JI. A scalable and impactful model for harnessing artificial intelligence and cybersecurity to revolutionize workforce development and empower marginalized youth. *International Journal of Multidisciplinary Research and Growth Evaluation*. 2022;3(1):714–9.
 13. Akinade AO, Adepoju PA, Ige AB, Afolabi AI, Amoo OO. Advancing segment routing technology: A new model for scalable and low-latency IP/MPLS backbone optimization. *Open Access Research Journal of Science and Technology*. 2022;5(2):77–95.
 14. Akinade AO, Adepoju PA, Ige AB, Afolabi AI, Amoo OO. A conceptual model for network security automation: Leveraging AI-driven frameworks to enhance multi-vendor infrastructure resilience. *International Journal of Science and Technology Research Archive*. 2021;1(1):39–59.
 15. Alli OI, Dada SA. Innovative Models for Tobacco Dependency Treatment: A Review of Advances in Integrated Care Approaches in High-Income Healthcare Systems. *IRE Journals*. 2021;5(6):273–82.
 16. Atta JA, Al Zoubi MAM, Temedie-Asogwa T, Amafah J. Comparing the cost-effectiveness of pharmaceutical vs. non-pharmaceutical interventions for diabetes management. 2021.
 17. Austin-Gabriel B, Hussain NY, Ige AB, Adepoju PA, Amoo OO, Afolabi AI. Advancing zero trust architecture with AI and data science for enterprise cybersecurity frameworks. *Open Access Research Journal of Engineering and Technology*. 2021;1(1):47–55.
 18. Bidemi AI, Oyindamola FO, Odum I, Stanley OE, Atta JA, Olatomide AM, *et al.* Challenges facing menstruating adolescents: A reproductive health approach. *Journal of Adolescent Health*. 2021;68(5):1–10.
 19. Bristol-Alagbariya B, Ayanponle OL, Ogedengbe DE. Strategic frameworks for contract management excellence in global energy HR operations. *GSC Advanced Research and Reviews*. 2022;11(3):150–7.
 20. Bristol-Alagbariya B, Ayanponle OL, Ogedengbe DE. Developing and implementing advanced performance management systems for enhanced organizational productivity. *World Journal of Advanced Science and Technology*. 2022;2(1):39–46.
 21. Charles OI, Hamza O, Eweje A, Collins A, Babatunde GO, Ubamadu BC. *International Journal of Social Science Exceptional Research*. 2022.
 22. Collins A, Hamza O, Eweje A. CI/CD pipelines and BI tools for automating cloud migration in telecom core networks: A conceptual framework. *IRE Journals*. 2022;5(10):323–4.
 23. Collins A, Hamza O, Eweje A. Revolutionizing edge computing in 5G networks through Kubernetes and DevOps practices. *IRE Journals*. 2022;5(7):462–3.
 24. Dienagha IN, Onyeke FO, Digitemie WN, Adekunle M. Strategic reviews of greenfield gas projects in Africa: Lessons learned for expanding regional energy infrastructure and security. 2021.
 25. Dirlikov E, Jahun I, Odafe SF, Obinna O, Onyenuobi C, Ifunanya M, *et al.* Section navigation rapid scale-up of an antiretroviral therapy program before and during the COVID-19 pandemic—nine states, Nigeria, March 31, 2019–September 30, 2020. 2021.
 26. Egbuonu ACC, Alaebo PO, Njoku CJ, Oriaku CE, Emeonye C. The role of l-arginine in prevention of testicular function toxicity induced by monosodium glutamate burden in Wistar rats. *The Nigerian Journal of Pharmacy*. 2022;56(2). Available from: <https://doi.org/10.51412/psnnp.2022.25>.
 27. Elujide I, Fashoto SG, Fashoto B, Mbunge E, Folorunso SO, Olamijuwon JO. *Informatics in Medicine Unlocked*. 2021;23:100545.
 28. Elujide I, Fashoto SG, Fashoto B, Mbunge E, Folorunso SO, Olamijuwon JO. Application of deep and machine learning techniques for multi-label classification performance on psychotic disorder diseases. *Informatics in Medicine Unlocked*. 2021;23:100545.
 29. Gbadegesin JO, Adekanmi AJ, Akinmoladun JA, Adelodun AM. Determination of fetal gestational age in singleton pregnancies: Accuracy of ultrasonographic placenta thickness and volume at a Nigerian tertiary hospital. *African Journal of Biomedical Research*. 2022;25(2):113–9.
 30. Govender P, Fashoto SG, Maharaj L, Adeleke MA, Mbunge E, Olamijuwon J, *et al.* The application of machine learning to predict genetic relatedness using human mtDNA hypervariable region I sequences. *PLOS One*. 2022;17(2):e0263790.
 31. Hamza O, Collins A, Eweje A. A comparative analysis of ETL techniques in telecom and financial data migration projects: Advancing best practices. *ICONIC*

- Research and Engineering Journals. 2022;6(1):737.
32. Hassan YG, Collins A, Babatunde GO, Alabi AA, Mustapha SD. AI-driven intrusion detection and threat modeling to prevent unauthorized access in smart manufacturing networks. *Artificial Intelligence (AI)*. 2021;16.
 33. Hussain NY, Austin-Gabriel B, Ige AB, Adepoju PA, Amoo OO, Afolabi AI. AI-driven predictive analytics for proactive security and optimization in critical infrastructure systems. *Open Access Research Journal of Science and Technology*. 2021;2(2):6–15.
 34. Ige AB, Austin-Gabriel B, Hussain NY, Adepoju PA, Amoo OO, Afolabi AI. Developing multimodal AI systems for comprehensive threat detection and geospatial risk mitigation. *Open Access Research Journal of Science and Technology*. 2022;6(1):93–101.
 35. Ike CC, Ige AB, Oladosu SA, Adepoju PA, Amoo OO, Afolabi AI. Redefining zero trust architecture in cloud networks: A conceptual shift towards granular, dynamic access control and policy enforcement. *Magna Scientia Advanced Research and Reviews*. 2021;2(1):74–86.
 36. Jahun I, Dirlikov E, Odafe S, Yakubu A, Boyd AT, Bachanas P, *et al.* Ensuring optimal community HIV testing services in Nigeria using an enhanced community case-finding package (ECCP), October 2019–March 2020: Acceleration to HIV epidemic control. *HIV/AIDS-Research and Palliative Care*. 2021;839–50.
 37. Jahun I, Said I, El-Imam I, Ehoche A, Dalhatu I, Yakubu A, *et al.* Optimizing community linkage to care and antiretroviral therapy initiation: Lessons from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) and their adaptation in Nigeria ART Surge. *PLOS One*. 2021;16(9):e0257476.
 38. Kuo YM, Nwankwo EI, Nussbaum RL, Rogers J, Maccacchini ML. Translational inhibition of α -synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice. *American Journal of Neurodegenerative Disease*. 2019;8(1):1.
 39. Matthew A, Opia FN, Matthew KA, Kumolu AF, Matthew TF. Cancer care management in the COVID-19 era: Challenges and adaptations in the global south. *Cancer*. 2021;2(6).
 40. Matthew KA, Akinwale FM, Opia FN, Adenike A. The relationship between oral contraceptive use, mammographic breast density, and breast cancer risk.
 41. Matthew KA, Opia FN, Matthew A, Kumolu AF, Matthew TF. Achieving personalized oncology care: Insights and challenges in Sub-Saharan Africa.
 42. Nasuti C, Falcioni ML, Nwankwo IE, Cantalamessa F, Gabbianelli R. Effect of permethrin plus antioxidants on locomotor activity and striatum in adolescent rats. *Toxicology*. 2008;251(1–3):45–50.
 43. Nwaozumudoh MO, Odio PE, Kokogho E, Olorunfemi TA, Adeniji IE, Sobowale A. Developing a conceptual framework for enhancing interbank currency operation accuracy in Nigeria's banking sector. *International Journal of Multidisciplinary Research and Growth Evaluation*. 2021;2(1):481–94.
 44. Odio PE, Kokogho E, Olorunfemi TA, Nwaozumudoh MO, Adeniji IE, Sobowale A. Innovative financial solutions: A conceptual framework for expanding SME portfolios in Nigeria's banking sector. *International Journal of Multidisciplinary Research and Growth Evaluation*. 2021;2(1):495–507.
 45. Oladosu SA, Ike CC, Adepoju PA, Afolabi AI, Ige AB, Amoo OO. The future of SD-WAN: A conceptual evolution from traditional WAN to autonomous, self-healing network systems. *Magna Scientia Advanced Research and Reviews*. 2021.
 46. Olamijuwon OJ. Real-time vision-based driver alertness monitoring using deep neural network architectures [Master's thesis]. Johannesburg (South Africa): University of the Witwatersrand; 2020.
 47. Oluokun OA. Design of a power system with significant mass and volume reductions, increased efficiency, and capability for space station operations using optimization approaches [Doctoral dissertation]. Lake Charles (LA): McNeese State University; 2021.
 48. Opia FN, Matthew KA, Matthew TF. Leveraging algorithmic and machine learning technologies for breast cancer management in sub-Saharan Africa. *Cancer Management Research and Practice*. 2022.
 49. Oyedokun OO. Green human resource management practices and its effect on the sustainable competitive edge in the Nigerian manufacturing industry (Dangote) [Doctoral dissertation]. Dublin (Ireland): Dublin Business School; 2019.
 50. Ozobu CO, Adikwu FE, Odujobi O, Onyekwe FO, Nwulu EO. A conceptual model for reducing occupational exposure risks in high-risk manufacturing and petrochemical industries through industrial hygiene practices. *Occupational Hygiene Research Journal*. 2022.
 51. Raman R, Dasgupta D, Ramasamy K, George R, Mohan V, Ting D. Using artificial intelligence for diabetic retinopathy screening: policy implications. *Indian Journal of Ophthalmology*. 2021;69(11):2993–8.
 52. Sendak M, Elish MC, Gao M, Futoma J, Ratliff W, Nichols M, *et al.* "The human body is a black box" supporting clinical decision-making with deep learning. In: *Proceedings of the 2020 Conference on Fairness, Accountability, and Transparency*; 2020. p. 99–109.
 53. Suri S, Chanda R, Bulut N, Narayana P, Zeng Y, Bailis P, *et al.* Leveraging organizational resources to adapt models to new data modalities. *arXiv preprint arXiv:2008.09983*. 2020.
 54. Tayebati KS, Nwankwo IE, Amenta F. Intranasal drug delivery to the central nervous system: present status and future outlook. *Current Pharmaceutical Design*. 2013;19(3):510–26.
 55. Tayebati KS, Tomassoni D, Nwankwo IE, Di Stefano A, Sozio P, Cerasa SL, *et al.* Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain. *CNS & Neurological Disorders – Drug Targets*. 2013;12(1):94–103.
 56. Tomassoni D, Amenta F, Amantini C, Farfariello V, Di Cesare Mannelli L, Nwankwo IE, *et al.* Brain activity of thioctic acid enantiomers: in vitro and in vivo studies in an animal model of cerebrovascular injury. *International Journal of Molecular Sciences*. 2013;14(3):4580–95.
 57. Tomassoni D, Amenta F, Di Cesare Mannelli L, Ghelardini C, Nwankwo IE, Pacini A, *et al.* Neuroprotective activity of thioctic acid in central nervous system lesions consequent to peripheral nerve injury. *BioMed Research International*. 2013;2013:985093.
 58. Tomassoni D, Catalani A, Cinque C, Di Tullio MA, Tayebati KS, Cadoni A, *et al.* Effects of cholinergic

- enhancing drugs on cholinergic transporters in the brain and peripheral blood lymphocytes of spontaneously hypertensive rats. *Current Alzheimer Research*. 2012;9(1):120–7.
59. Tomassoni D, Nwankwo IE, Gabrielli MG, Bhatt S, Muhammad AB, Lokhandwala MF, *et al*. Astrogliosis in the brain of obese Zucker rat: a model of metabolic syndrome. *Neuroscience Letters*. 2013;543:136–41.
60. Wang D, Wang L, Zhang Z, Wang D, Zhu H, Gao Y, *et al*. “Brilliant AI doctor” in rural clinics: challenges in AI-powered clinical decision support system deployment. In: *Proceedings of the 2021 CHI Conference on Human Factors in Computing Systems*; 2021. p. 1–18.